Comparative Pharmacology
Head-to-head clinical analysis: GLIADEL versus HEXALEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLIADEL versus HEXALEN.
GLIADEL vs HEXALEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLIADEL (carmustine implant) is a biodegradable wafer that delivers carmustine, a nitrosourea alkylating agent, directly into the tumor resection cavity. Carmustine alkylates DNA and RNA, leading to cross-linking and inhibition of DNA replication, ultimately causing cell death. It is cell cycle phase nonspecific.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Gliadel (carmustine) implant is administered intraoperatively as 8 wafers, each containing 7.7 mg carmustine, placed in the resection cavity after tumor debulking. Maximum dose is 61.6 mg (8 wafers).
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 hours for the active dianhydrogalactitol metabolite. Clinical context: short half-life supports local interstitial delivery with minimal systemic accumulation.
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Primarily renal (60-70% as unchanged drug and metabolites) and biliary/fecal (15-20%). Approximately 10-15% is eliminated via exhaled air as CO2.
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Category C
Category C
Alkylating Agent
Alkylating Agent